NUC-7738 treatment for advanced solid cancers and lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Skin clinical trials.
This early-phase study tests how safe NUC-7738 is and how it works in people with advanced solid tumors and certain lymphomas. Some participants may also receive pembrolizumab for specific cancers, aiming to improve cancer control while carefully monitoring side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent and are age 18 or older.
- Your cancer is an advanced solid tumor or one of the listed lymphomas, and you have measurable (or otherwise detectable) disease.
- You are generally well enough to do daily activities (performance status 0–1) and you likely can live at least 12 weeks.
- Your blood counts and organ tests (bone marrow, liver, kidneys) are at acceptable levels.
- You can follow study rules and may need repeat tumor biopsies (or an eligible recent stored biopsy).
- If you can become pregnant, you must have a negative pregnancy test and use two reliable birth-control methods for the study period and after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a new treatment in people with advanced (locally advanced or metastatic) solid tumors that have worsened or cannot be treated with standard therapies. It may help shrink tumors or slow growth, and it also helps doctors learn the safest way to use the medicine.
This trial tests a drug called pembrolizumab (Keytruda) to see if it helps people with several types of cancer, including relapsed or refractory lymphoma, melanoma, MSI-high or TMB-high solid tumors, and Merkel cell carcinoma. The goal is to understand if this immunotherapy can shrink or control the cancer.
This Phase 1/2 study tests a medicine injected directly into a tumor, alone or with pembrolizumab (an immune-therapy drug given through a vein). It is for people with advanced or metastatic solid cancers that have grown despite standard treatments, aiming to improve tumor control.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a new drug called N-3C01, alone or combined with immune-boosting medications, in patients whose advanced cancer has stopped responding to standard treatments. The goal is to see if this approach can slow or shrink tumors that have become resistant to other therapies.
This Phase 1 trial studies a new experimental immunotherapy (MBS8) for people with advanced solid tumors, focusing first on safety and early signs of benefit. Depending on your cancer type and past treatments, you may receive MBS8 alone or combined with pembrolizumab.
Hear when a new Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.